|Description||MLi-2 is a potent, orally available and brain penetrant inhibitor of LRRK2 (IC50= 0.76 nM) with excellent selectivity that shows >295-fold selectivity for over 300 kinases and a diverse panel of receptors and ion channels.|
|Brife Description||A potent and selective LRRK2 inhibitor (IC50= 0.76 nM)|
|Synonyms||(2R,6S)-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1H-indazol-3-yl]pyrimidin-4-yl]morpholine; MLi-2; MLi 2; MLi2|
|Solubility||DMSO: ≥ 26 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||625.8±55.0 ℃ at 760 Torr|
PF06447475 is a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Leucine rich repeat kinase 2 (LRRK2) has been genetically ...
CZC-25146 is a compound that acts as an inhibitor of LRRK2, a factor in the expression of Parkinsons
Potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively). Atte...
MLi-2 is a potent, orally available and brain penetrant inhibitor of LRRK2 (IC50= 0.76 nM) with excellent selectivity that shows >295-fold selectivity for over ...
JH-II-127, a Pyrrolopyrimidine derivative, is a highly potent, selective, and brain penetrant LRRK2 inhibitor, of both wild-type and G2019S mutant LRRK2. IC50: ...
LRRK2-IN-1 is a benzodiazepine based derivative and is known as a selective inhibitor of the Parkinson's disease kinase LRRK2.
GNE-9605 retained excellent predicted human metabolic stability when assayed in human liver microsomes and hepatocytes. In addition, no reversible or time-depen...
HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM)<br /> <strong>IC50 Value</strong>: 23.3 nM ...
GSK2578215A induces a dose-dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and LRRK2[G2019S] stably transfected into HEK293 ce...
CZC-25146 is a compound that acts as an inhibitor of LRRK2, a factor in the expression of Parkinsons’s disease, and is ATP-competitive.